SNYR_OUT_1 [2025-04-28 12:41:43 -0400] 3675 Bytes | 956 tokens | Cum: 956 tkns (11.95% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Synergy CHC (SNYR) which is at $1.90 up from $1.61. So, I pulled together a bunch of data for you to look over real fast. It's still early, 12:41 PM on Mon Apr 28, 2025. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: Synergy CHC (SNYR)
IPO: 2013-11-07 (11 Years Ago)
Market Cap: $15,344,068
Shares Outstanding: 8,750,000
Industry: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Exchange: XNAS
Description: Synergy CHC Corp is a provider of consumer health care, beauty, and lifestyle products. It is engaged in the business of marketing and distributing consumer branded products through various distribution channels in the health and wellness industry. The company's products include FOCUSfactor, Flat Tummy Tea, Hand MD, and Neuragen amongst others. Flat Tummy is a lifestyle and wellness brand that provides a suite of nutritional products to help women achieve their nutrition and weight management goals.

Here’s a list of headlines for Synergy CHC:

Mar-31-25 08:00AM - Synergy CHC Reports its Eighth Consecutive Quarter of Profitability and its Fourth Quarter and Full Year 2024 Financial Results
Mar-20-25 04:05PM - Synergy CHC Corp. Announces Fourth Quarter and Full Year 2024 Earnings and Conference Call Information
Mar-03-25 04:05PM - Synergy CHC to Attend 37th Annual ROTH Conference
Dec-06-24 08:00AM - Synergy CHC Reports its Seventh Consecutive Quarter of Profitability and its Third Quarter 2024 Financial Results
Nov-26-24 04:05PM - Synergy CHC Corp. Announces Third Quarter 2024 Earnings and Conference Call Information
Oct-24-24 05:00PM - Synergy CHC Corp. Announces Closing of Initial Public Offering
Oct-22-24 07:25PM - Synergy CHC Corp. Prices $10.35 Million Initial Public Offering

Prior AI Reports for SNYR:
1. 2025-04-15 – Score: 15 – Target: 1.6000 – Highs: 4.0800 / 2.5800 / 2.73
synergy-chc-faces-severe-downturn-amid-insider-buys

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-11-06T11:00:00Z - Outdoor Solar Furniture Market Expected to Reach USD 564.71 Mn by 2032, Growing CAGR at 15.47% From 2024-2032 | Introspective Market Research

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Synergy CHC (SNYR).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

SNYR_OUT_3 [2025-04-28 12:41:44 -0400] 1039 Bytes | 307 tokens | Cum: 1265 tkns (15.81% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-17T20:21:49Z - Synergy CHC Corp. to Be Featured in Six-Part National Media Series on "New to The Street" Series Inc...
A2 - 2025-04-17T20:46:41Z - Synergy CHC Corp. to Be Featured in Six-Part National Media Series on "New to The Street" Series Inc...
A3 - 2025-04-17T20:26:00Z - Synergy CHC Corp. to Be Featured in Six-Part National Media Series on New to The Street Series Inclu...
A4 - 2025-04-15T14:13:21Z - Nasdaq Surges 100 Points; Bank of America Earnings Top Views - Bank of America (NYSE:BAC), Webull (N...
A5 - 2025-04-15T09:19:09Z - Why Ericsson Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Applied D...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

SNYR_OUT_5 [2025-04-28 12:41:45 -0400] 1181 Bytes | 316 tokens | Cum: 1583 tkns (19.79% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**Synergy CHC Corp. to Be Featured in Six-Part National Media Series on "New to The Street" Series Includes Monthly Broadcasts, Earned Media, Iconic Billboards, and T.V. Commercials Across U.S. Markets**Date: 2025-04-17Source: {'uri': 'eagletribune.com', 'dataType': 'news', 'title': 'Eagle-Tribune'}URL: https://www.eagletribune.com/region/synergy-chc-corp-to-be-featured-in-six-part-national-media-series-on-new-to/article_798293d2-e043-52a9-a299-a165a4985118.htmlNEW YORK CITY, NEW YORK / ACCESS Newswire / April 17, 2025 / Synergy CHC Corp. (NASDAQ:SNYR), a leading consumer health and wellness company, proudly announces its participation in a six-part featured series on the acclaimed business television program "New to The Street", airing as sponsored programming on FOX Business and Bloomberg Television.

The series will deliver monthly nationwide broadcasts, a wave of earned media pla

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_7 [2025-04-28 12:41:45 -0400] 670 Bytes | 155 tokens | Cum: 1740 tkns (21.75% of 8k)
==========================================================================

Showing A1 (chunk 2 of 2): cements, TV commercials, and exclusive billboard exposure through a strategic partnership with Accel Media International (AMI). Each segment will spotlight Synergy's product lines, innovations, and growth story, and will be amplified through New to The Street's platform, including its 2.4 million+ YouTube subscribers, national television syndication, and Times Square digital displays.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_9 [2025-04-28 12:41:47 -0400] 1070 Bytes | 256 tokens | Cum: 1998 tkns (24.98% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the audited condensed CONS financial statements an...

S2 - 2025-03-31 8-K Item 2.02. Results of Oper and Fin Cond.

On March 31, 2025, Synergy CHC Corp. (the Company) issued a press release announcing its financial and operating results for the quarter and year ended December 31, 2024. A copy of the press release is furnished herewith...

S3 - 2025-03-31 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the audited condensed CONS financial statements an...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SNYR_OUT_11 [2025-04-28 12:41:48 -0400] 1181 Bytes | 234 tokens | Cum: 2234 tkns (27.93% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the audited condensed consolidated financial statements and the notes thereto contained elsewhere in this Annual Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Our actual results may differ significantly from the results, expectations and plans discussed in these forward-looking statements.

Overview

We are a provider of consumer health care, beauty, and lifestyle products. Our current brand portfolio consists of two core brands: FOCUSfactor, a clinically-tested brain health supplement (this study was performed independently and is not related to any FDA

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_13 [2025-04-28 12:41:48 -0400] 1181 Bytes | 236 tokens | Cum: 2472 tkns (30.90% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): -approved IND application) that has been shown to improve memory, concentration and focus and Flat Tummy, a lifestyle brand that provides a suite of nutritional products to help women achieve their weight management goals.

Our managements discussion and analysis of our financial condition and results of operations are only based on our current business and should be read in conjunction with our unaudited interim condensed consolidated financial statements and audited consolidated financial statements and accompanying notes thereto included elsewhere in this prospectus. Key factors affecting our results of operations include revenues, cost of revenue, operating expenses and income and taxation.

Non-GAAP Financial Measures

We currently focus on EBITDA to evaluate our business relationships and our resulting operating performance and financial position. EBITDA is defined as net income p

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_15 [2025-04-28 12:41:49 -0400] 1181 Bytes | 313 tokens | Cum: 2787 tkns (34.84% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): lus interest expense, income tax expense, depreciation and amortization.

We believe that EBITDA, viewed in addition to, and not in lieu of, our reported results in accordance with accounting principles generally accepted in the United States (U.S. GAAP), provides useful information to investors.

##TABLE_START Year Ended December 31, 2024 Year Ended December 31, 2023 Net income $ 2,124,976 $ 6,338,750 Interest income (1,523 ) (1,616 ) Interest expense 4,105,198 4,236,149 Taxes 102,085 234,980 Depreciation and amortization 133,334 33,333 EBITDA $ 6,464,070 $ 10,841,596 ##TABLE_END

EBITDA is considered non-GAAP financial measures. EBITDA represents earnings before interest, taxes, depreciation and amortization. Our definition of EBITDA might not be comparable to similarly titled measures reported by other companies.

Results of Operations for the Years Ended December 31, 2024 and Decembe

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_17 [2025-04-28 12:41:50 -0400] 1181 Bytes | 343 tokens | Cum: 3132 tkns (39.15% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): r 31, 2023

During both 2024 and 2023, we focused on developing our currently owned brands into new markets and by product extensions.

Revenue

For the year ended December 31, 2024, we had revenues of $34,834,243 from sales of our products, as compared to revenue of $42,777,633 for the year ended December 31, 2023. This is comprised of the following categories:

##TABLE_START December 31, 2024 December 31, 2023 Nutraceuticals $ 34,817,333 $ 42,753,052 Consumer Goods 16,910 24,581 $ 34,834,243 $ 42,777,633 ##TABLE_END

For the year ended December 31, 2024, our Nutraceuticals revenue consisted of $30,798,145 from our FOCUSfactor brand and $4,019,188 from our Flat Tummy brand, as compared to $37,202,521 and $5,550,531, respectively, for the year ended December 31, 2023.

The decrease in our Nutraceutical category was due to undertaking a rebranding and packaging upgrade for FOCUSfactor t

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_19 [2025-04-28 12:41:51 -0400] 1181 Bytes | 309 tokens | Cum: 3443 tkns (43.04% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): hat resulted in customers selling through their existing inventory before bringing in the new packaging. The decrease in the Consumer Goods category is due to normalization of business after the 2019 launch of our online application.

Cost of Sales

For the year ended December 31, 2024, our cost of sales was $11,191,224. Our cost of sales for the year ended December 31, 2023 was $10,697,323. The increase in cost of sales was primarily due to a settlement with a supplier in 2023 resulting in a reduction in cost of sales for 2023.

Gross Profit

Gross profit was $23,643,019, or 68% of revenue for the year ended December 31, 2024, as compared to gross profit of $32,080,310 or 75% of revenue for the same period in 2023, a decrease of $8,437,291 or 26%. The decrease in gross profit is largely related to the decrease in net sales due to the rebranding of FOCUSfactor.

Operating Expenses

Se

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_21 [2025-04-28 12:41:52 -0400] 790 Bytes | 206 tokens | Cum: 3651 tkns (45.64% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): lling and Marketing Expenses

For the year ended December 31, 2024, our selling and marketing expenses were $12,991,431 as compared to $15,188,528 for the year ended December 31, 2023. The decrease is due to management of expenses.

General and Administrative Expenses

For the year ended December 31, 2024, our general and administrative expenses were $4,717,006. For the year ended December 31, 2023, our general and administrative expenses were $6,051,703. The decrease is largely due to management ...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_23 [2025-04-28 12:42:00 -0400] 6404 Bytes | 1717 tokens | Cum: 5370 tkns (67.12% of 8k)
==========================================================================

This is our set of metrics for Synergy CHC.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+------------------------+
| Volume: 79,010 | Perf Month: -40.50% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 1.07M | Perf Quarter: -49.68% | Short Float: 2.80% | ROE: - |
+--------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 0.15 | Index: - | Short Ratio: 0.06 | ROI: - |
+--------------------+-----------------------+------------------------+------------------------+
| RSI (14): 40.73 | Market Cap: 16.72M | Short Interest: 0.06M | Sales Surprise: -2.36% |
+--------------------+-----------------------+------------------------+------------------------+
| ATR (14): 0.51 | Shs Outstand: 8.54M | Beta: - | EPS Surprise: -90.00% |
+--------------------+-----------------------+------------------------+------------------------+
| SMA20: -10.40% | Shs Float: 2.30M | Sales Q/Q: -4.95% | P/E: 1.05 |
+--------------------+-----------------------+------------------------+------------------------+
| SMA50: -34.97% | Inst Own: 10.56% | Sales past 5Y: -3.60% | Earnings: Mar 31 BMO |
+--------------------+-----------------------+------------------------+------------------------+
| SMA200: -36.93% | Insider Own: 73.76% | Employees: 21 | |
+--------------------+-----------------------+------------------------+------------------------+
| Perf Week: -28.73% | Insider Trans: 0.32% | Debt/Eq: - | |
+--------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading by Synergy CHC officers or majority shareholders (if available).

Inside Trans: Synergy CHC Corp. (SNYR) by Ross Jack (CEO and Chairman) on 2025-01-23
- Common Stock, par value $0.00001 per share: 100 shares at $4.09 (D)
- Common Stock, par value $0.00001 per share: 300 shares at $3.89 (D)
- Common Stock, par value $0.00001 per share: 400 shares at $3.84 (D)
- Common Stock, par value $0.00001 per share: 1300 shares at $4.21 (D)
- Common Stock, par value $0.00001 per share: 700 shares at $4.35 (D)
- Common Stock, par value $0.00001 per share: 500 shares at $4.23 (D)
- Common Stock, par value $0.00001 per share: 600 shares at $3.92 (D)
- Common Stock, par value $0.00001 per share: 500 shares at $4.21 (D)
- Common Stock, par value $0.00001 per share: 950 shares at $4.17 (D)
- Common Stock, par value $0.00001 per share: 800 shares at $4.14 (D)
- Common Stock, par value $0.00001 per share: 1800 shares at $3.91 (D)
- Common Stock, par value $0.00001 per share: 1600 shares at $3.8 (D)
- Common Stock, par value $0.00001 per share: 500 shares at $3.41 (D)
- Common Stock, par value $0.00001 per share: 900 shares at $3.51 (D)
- Common Stock, par value $0.00001 per share: 600 shares at $3.74 (D)
- Common Stock, par value $0.00001 per share: 900 shares at $3.67 (D)
- Common Stock, par value $0.00001 per share: 950 shares at $3.69 (D)
- Common Stock, par value $0.00001 per share: 300 shares at $3.69 (D)
- Common Stock, par value $0.00001 per share: 1200 shares at $3.92 (D)
- Common Stock, par value $0.00001 per share: 300 shares at $4 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.9
Average Volume: 3341892.7
30-Day High: 2.68
30-Day Low: 1.61
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Synergy CHC (SNYR).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Synergy CHC.

2) MARKET_SCORE[]
This conversation was initiated because SNYR is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for SNYR.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, SNYR could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect SNYR to increase 50% from its current price of $2.58, say: PRICE_TARGET[3.87]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Synergy CHC.

11) ETHICAL_RATING[]
Rate Synergy CHC’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Synergy CHC.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

SNYR_IN_25 [2025-04-28 12:42:00 -0400] 126 Bytes | 29 tokens | Cum: 5644 tkns (70.55% of 8k)
==========================================================================

====================================
[2025-04-28 12:42:00] # Analysis Completed
Elapsed Time: 18.18 seconds